High glucose exposure drives intestinal barrier dysfunction by altering its morphological, structural and functional properties-Reference-Cited by-同舟云学术

High glucose exposure drives intestinal barrier dysfunction by altering its morphological, structural and functional properties

Published:2023-10 Issue: Volume:216 Page:115765
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Dubois Nolwenn,Muñoz-Garcia Javier^ORCID,Heymann Dominique,Renodon-Cornière Axelle^ORCID

Funder

Conseil Régional des Pays de la Loire

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference67 articles.

1. American Diabetes Association Diabetes in Hospitals Writing Committee Management of Diabetes and Hyperglycemia in Hospitals;Clement;Diabetes Care,2004

2. Chronic Hyperglycemia Mediated Physiological Alteration and Metabolic Distortion Leads to Organ Dysfunction, Infection, Cancer Progression and Other Pathophysiological Consequences: An Update on Glucose Toxicity;Giri;Biomed. Pharmacother.,2018

3. The Epidemiology of Obesity: A Big Picture;Hruby;Pharmacoeconomics,2015

4. Regional Office for Europe WHO European Regional Obesity Report 2022; World Health Organization. Regional Office for;World Health Organization;Europe,2022

5. Hyperglycemia, a Neglected Factor during Cancer Progression;Duan;Biomed. Res. Int.,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperglycemic environments directly compromise intestinal epithelial barrier function in an organoid model and hyaluronan (∼35 kDa) protects via a layilin dependent mechanism;Matrix Biology;2024-11

2. Improving the Accuracy of Permeability Data to Gain Predictive Power: Assessing Sources of Variability in Assays Using Cell Monolayers;Membranes;2024-07-14

3. Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise;Frontiers in Physiology;2024-07-08

4. Difference in Prognosis of Colorectal Cancer Patients with or without Diabetes Mellitus;Advances in Clinical Medicine;2024

5. Modulating intestinal barrier function by sphingosine-1-phosphate receptor 1 specific agonist SEW2871 attenuated ANIT-induced cholestatic hepatitis via the gut-liver axis;International Immunopharmacology;2023-12